NAMS MENOPAUSE CERTIFICATION EXAM 2026/2027 |
Complete Practice Questions with Evidence-Based Solutions
| CMP Certification | Pass Guaranteed - A+ Graded
SECTION 1: PHYSIOLOGY OF MENOPAUSE AND AGING (25 Questions)
Q1: A 48-year-old woman presents with irregular menstrual cycles and occasional hot
flashes. Her FSH level is 18 mIU/mL (normal follicular phase 3.0-20.0). According to the
STRAW+10 staging system, which reproductive aging stage is she most likely in?
A. Late reproductive stage
B. Early menopausal transition (Stage -2) [CORRECT]
C. Late menopausal transition (Stage -1)
D. Early postmenopause (Stage +1)
Correct Answer: B
Rationale: The STRAW+10 staging system defines the early menopausal transition
(Stage -2) by increased variability in menstrual cycle length (>7 days difference from
normal), elevated FSH (variable, often 15-25 mIU/mL), and emerging vasomotor
symptoms. A is incorrect because late reproductive stage maintains regular cycles with
subtle FSH elevation. C is incorrect because late menopausal transition (Stage -1)
features cycle length >60 days or amenorrhea 2-11 months with FSH typically >25
mIU/mL. D is incorrect because early postmenopause requires 12+ months
amenorrhea. This patient's irregular cycles with moderate FSH elevation and emerging
symptoms characterize early transition. Understanding STRAW+10 enables appropriate
counseling about fertility potential and symptom management timing.
,Q2: Which hormonal change is the primary driver of vasomotor symptoms (VMS) during
the menopausal transition?
A. Absolute estrogen deficiency
B. Erratic estrogen fluctuations and narrowing of the thermoneutral zone [CORRECT]
C. Progesterone dominance
D. Elevated inhibin B levels
Correct Answer: B
Rationale: Vasomotor symptoms result primarily from erratic estrogen fluctuations (not
absolute deficiency) causing neuroendocrine dysregulation of thermoregulation. The
thermoneutral zone narrows, triggering heat dissipation responses (hot flashes) with
minimal core temperature changes. Estrogen withdrawal increases norepinephrine and
serotonin, altering hypothalamic set-point. A is incorrect because absolute deficiency
characterizes postmenopause when VMS often diminish. C is incorrect because
progesterone declines steadily without dominance. D is incorrect because inhibin B falls
early in transition, contributing to FSH rise but not directly to VMS. This pathophysiology
explains why hormone therapy stabilizes estrogen levels more than replacing absolute
deficiency.
Q3: A 52-year-old woman, 18 months postmenopausal, has elevated LH (45 mIU/mL)
and FSH (78 mIU/mL) with estradiol <20 pg/mL. Which physiological explanation
accounts for these findings?
A. Pituitary adenoma secreting gonadotropins
B. Loss of negative feedback from ovarian estradiol and inhibin [CORRECT]
C. Primary hypothalamic dysfunction
D. Excessive aromatase activity in adipose tissue
Correct Answer: B
,Rationale: Postmenopausal gonadotropin elevation results from loss of ovarian
negative feedback. Estradiol and inhibin normally suppress GnRH pulsatility and
gonadotropin secretion; their decline removes this inhibition, causing compensatory
LH/FSH rise. A is incorrect because pituitary adenomas cause isolated hormonal
excess with mass effects, not this pattern. C is incorrect because hypothalamic
dysfunction would typically decrease GnRH/gonadotropins. D is incorrect because
adipose aromatization converts androgens to estrone (weak estrogen), insufficient for
feedback. This neuroendocrine pattern confirms ovarian failure and distinguishes
menopause from other amenorrhea causes.
Q4: Which change in androgen production occurs during the menopausal transition?
A. Significant increase in ovarian testosterone production
B. 50% decline in ovarian testosterone and near-total loss of estradiol [CORRECT]
C. Maintenance of pre-menopausal androgen levels through adrenal compensation
D. Complete cessation of all androgen production
Correct Answer: B
Rationale: Menopause causes ~50% decline in ovarian testosterone (stroma/theca
continues some production) and >95% decline in estradiol. Adrenal DHEA/DHEAS
decline gradually with aging (adrenopause), not compensating for ovarian loss. A is
incorrect because ovarian testosterone decreases, though less dramatically than
estrogen. C is incorrect because adrenal compensation for ovarian androgens is
incomplete. D is incorrect because ovarian and adrenal androgen production continues,
just reduced. This androgen decline contributes to decreased libido, energy, and bone
density in some women, though androgen replacement remains controversial.
Q5: The "estrogen window" or timing hypothesis regarding hormone therapy and
cardiovascular protection is supported by which physiological mechanism?
, A. Estrogen prevents atherosclerosis regardless of age or time since menopause
B. Estrogen preserves endothelial function and prevents plaque destabilization when
started before significant atherosclerosis develops [CORRECT]
C. Estrogen causes regression of established coronary plaques in older women
D. Progesterone is the primary cardioprotective hormone when combined with estrogen
Correct Answer: B
Rationale: The timing hypothesis, supported by WHI subgroup analyses and ELITE trial,
proposes estrogen benefits endothelial function, improves insulin sensitivity, and
prevents early atherosclerosis when initiated in recently menopausal women (<10 years
or age <60). Once atherosclerosis is established, estrogen may cause plaque instability
and thrombosis. A is incorrect because WHI showed harm in older women. C is
incorrect because estrogen doesn't regress established plaques. D is incorrect because
progestogens may attenuate some estrogen benefits but aren't primarily
cardioprotective. This guides HT initiation decisions: preferentially for symptomatic
women <60 or <10 years since menopause.
Q6: A 45-year-old woman with irregular cycles has AMH <0.1 ng/mL. Which statement
about ovarian reserve is correct?
A. She has excellent fertility potential for the next 5 years
B. She will likely experience menopause within 1-3 years [CORRECT]
C. AMH is unreliable for predicting menopause timing
D. Her ovarian reserve is comparable to a 25-year-old
Correct Answer: B
Rationale: AMH <0.1 ng/mL indicates severely diminished ovarian reserve, predicting
menopause within 1-3 years regardless of cycle regularity. AMH reflects antral follicle
count and is the best biomarker for remaining reproductive lifespan. A is incorrect
because fertility potential is minimal. C is incorrect because AMH is highly predictive of
Complete Practice Questions with Evidence-Based Solutions
| CMP Certification | Pass Guaranteed - A+ Graded
SECTION 1: PHYSIOLOGY OF MENOPAUSE AND AGING (25 Questions)
Q1: A 48-year-old woman presents with irregular menstrual cycles and occasional hot
flashes. Her FSH level is 18 mIU/mL (normal follicular phase 3.0-20.0). According to the
STRAW+10 staging system, which reproductive aging stage is she most likely in?
A. Late reproductive stage
B. Early menopausal transition (Stage -2) [CORRECT]
C. Late menopausal transition (Stage -1)
D. Early postmenopause (Stage +1)
Correct Answer: B
Rationale: The STRAW+10 staging system defines the early menopausal transition
(Stage -2) by increased variability in menstrual cycle length (>7 days difference from
normal), elevated FSH (variable, often 15-25 mIU/mL), and emerging vasomotor
symptoms. A is incorrect because late reproductive stage maintains regular cycles with
subtle FSH elevation. C is incorrect because late menopausal transition (Stage -1)
features cycle length >60 days or amenorrhea 2-11 months with FSH typically >25
mIU/mL. D is incorrect because early postmenopause requires 12+ months
amenorrhea. This patient's irregular cycles with moderate FSH elevation and emerging
symptoms characterize early transition. Understanding STRAW+10 enables appropriate
counseling about fertility potential and symptom management timing.
,Q2: Which hormonal change is the primary driver of vasomotor symptoms (VMS) during
the menopausal transition?
A. Absolute estrogen deficiency
B. Erratic estrogen fluctuations and narrowing of the thermoneutral zone [CORRECT]
C. Progesterone dominance
D. Elevated inhibin B levels
Correct Answer: B
Rationale: Vasomotor symptoms result primarily from erratic estrogen fluctuations (not
absolute deficiency) causing neuroendocrine dysregulation of thermoregulation. The
thermoneutral zone narrows, triggering heat dissipation responses (hot flashes) with
minimal core temperature changes. Estrogen withdrawal increases norepinephrine and
serotonin, altering hypothalamic set-point. A is incorrect because absolute deficiency
characterizes postmenopause when VMS often diminish. C is incorrect because
progesterone declines steadily without dominance. D is incorrect because inhibin B falls
early in transition, contributing to FSH rise but not directly to VMS. This pathophysiology
explains why hormone therapy stabilizes estrogen levels more than replacing absolute
deficiency.
Q3: A 52-year-old woman, 18 months postmenopausal, has elevated LH (45 mIU/mL)
and FSH (78 mIU/mL) with estradiol <20 pg/mL. Which physiological explanation
accounts for these findings?
A. Pituitary adenoma secreting gonadotropins
B. Loss of negative feedback from ovarian estradiol and inhibin [CORRECT]
C. Primary hypothalamic dysfunction
D. Excessive aromatase activity in adipose tissue
Correct Answer: B
,Rationale: Postmenopausal gonadotropin elevation results from loss of ovarian
negative feedback. Estradiol and inhibin normally suppress GnRH pulsatility and
gonadotropin secretion; their decline removes this inhibition, causing compensatory
LH/FSH rise. A is incorrect because pituitary adenomas cause isolated hormonal
excess with mass effects, not this pattern. C is incorrect because hypothalamic
dysfunction would typically decrease GnRH/gonadotropins. D is incorrect because
adipose aromatization converts androgens to estrone (weak estrogen), insufficient for
feedback. This neuroendocrine pattern confirms ovarian failure and distinguishes
menopause from other amenorrhea causes.
Q4: Which change in androgen production occurs during the menopausal transition?
A. Significant increase in ovarian testosterone production
B. 50% decline in ovarian testosterone and near-total loss of estradiol [CORRECT]
C. Maintenance of pre-menopausal androgen levels through adrenal compensation
D. Complete cessation of all androgen production
Correct Answer: B
Rationale: Menopause causes ~50% decline in ovarian testosterone (stroma/theca
continues some production) and >95% decline in estradiol. Adrenal DHEA/DHEAS
decline gradually with aging (adrenopause), not compensating for ovarian loss. A is
incorrect because ovarian testosterone decreases, though less dramatically than
estrogen. C is incorrect because adrenal compensation for ovarian androgens is
incomplete. D is incorrect because ovarian and adrenal androgen production continues,
just reduced. This androgen decline contributes to decreased libido, energy, and bone
density in some women, though androgen replacement remains controversial.
Q5: The "estrogen window" or timing hypothesis regarding hormone therapy and
cardiovascular protection is supported by which physiological mechanism?
, A. Estrogen prevents atherosclerosis regardless of age or time since menopause
B. Estrogen preserves endothelial function and prevents plaque destabilization when
started before significant atherosclerosis develops [CORRECT]
C. Estrogen causes regression of established coronary plaques in older women
D. Progesterone is the primary cardioprotective hormone when combined with estrogen
Correct Answer: B
Rationale: The timing hypothesis, supported by WHI subgroup analyses and ELITE trial,
proposes estrogen benefits endothelial function, improves insulin sensitivity, and
prevents early atherosclerosis when initiated in recently menopausal women (<10 years
or age <60). Once atherosclerosis is established, estrogen may cause plaque instability
and thrombosis. A is incorrect because WHI showed harm in older women. C is
incorrect because estrogen doesn't regress established plaques. D is incorrect because
progestogens may attenuate some estrogen benefits but aren't primarily
cardioprotective. This guides HT initiation decisions: preferentially for symptomatic
women <60 or <10 years since menopause.
Q6: A 45-year-old woman with irregular cycles has AMH <0.1 ng/mL. Which statement
about ovarian reserve is correct?
A. She has excellent fertility potential for the next 5 years
B. She will likely experience menopause within 1-3 years [CORRECT]
C. AMH is unreliable for predicting menopause timing
D. Her ovarian reserve is comparable to a 25-year-old
Correct Answer: B
Rationale: AMH <0.1 ng/mL indicates severely diminished ovarian reserve, predicting
menopause within 1-3 years regardless of cycle regularity. AMH reflects antral follicle
count and is the best biomarker for remaining reproductive lifespan. A is incorrect
because fertility potential is minimal. C is incorrect because AMH is highly predictive of
